Orum Therapeutics, Inc.
KOSDAQTotal Valuation
Orum Therapeutics, Inc. carries a market capitalization of 1.11T, placing it among publicly traded companies globally. Its enterprise value stands at 1.61T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.11T |
| Enterprise Value | 1.61T |
Valuation Ratios
The price-to-sales ratio is 89,983.42, and the price-to-book ratio stands at 366.27.
| PE Ratio | N/A |
| PS Ratio | 89,983.42 |
| PB Ratio | 366.27 |
| P/TBV Ratio | 15.51 |
| P/FCF Ratio | -42.79 |
| P/OCF Ratio | -42.14 |
Enterprise Valuation
| EV / Sales | 77,969.46 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Orum Therapeutics, Inc. maintains a current ratio of 1.63, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.26, indicating elevated leverage, while an interest coverage ratio of -32.14 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.63 |
| Quick Ratio | 1.62 |
| Debt / Equity | 22.26 |
| Debt / EBITDA | -0.44 |
| Interest Coverage | -32.14 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -19.29 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Orum Therapeutics, Inc.'s stock has gained approximately 173.29843% over the past 52 weeks. The 50-day moving average sits at 70,262.00, while the 200-day moving average is 81,248.50.
| Beta (5Y) | N/A |
| 52-Week Price Change | 173.29843% |
| 50-Day Moving Average | 70,262.00 |
| 200-Day Moving Average | 81,248.50 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Orum Therapeutics, Inc. generated 20.61M in revenue and converted that into -48.65B in net income, yielding earnings per share of -2,255.73. EBITDA reached -60.27B, while operating income came in at -60.27B.
| Revenue | 20.61M |
| Gross Profit | 20.61M |
| Operating Income | -60.27B |
| Pretax Income | -50.83B |
| Net Income | -48.65B |
| EBITDA | -60.27B |
| EBIT | -60.27B |
| Earnings Per Share (EPS) | -2,255.73 |
Balance Sheet
Orum Therapeutics, Inc. holds 274.23B in cash and equivalents against 26.61B in total debt, resulting in a net debt position of -113.10B. Total book value stands at 5.06B, with working capital of 107.47B providing operational flexibility.
| Cash & Cash Equivalents | 274.23B |
| Total Debt | 26.61B |
| Net Debt | -113.10B |
| Equity (Book Value) | 5.06B |
| Book Value Per Share | 234.80 |
| Working Capital | 107.47B |
Cash Flow
Orum Therapeutics, Inc. produced -44.02B in operating cash flow over the past twelve months. After subtracting -669.18M in capital expenditures, free cash flow totaled -44.68B - equivalent to -2,072.04 per share.
| Operating Cash Flow | -44.02B |
| Capital Expenditures | -669.18M |
| Free Cash Flow | -44.68B |
| FCF Per Share | -2,072.04 |
Margins
Orum Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -292,397.98 and net profit margin of -236,020.95 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -292,397.98 |
| Pretax Margin | -246,612.54 |
| Profit Margin | -236,020.95 |
| EBITDA Margin | -292,397.98 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -7.97 |
| FCF Yield | -2.34 |
Scores
Orum Therapeutics, Inc. posts an Altman Z-Score of 5.55, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.55 |